Clinical trial · Interventional
The Effect of a Gamified Neuropathy Management Application on Cancer Behavior in Cancer Patients Undergoing Chemotherapy
The Effect of a Gamified Neuropathy Management Application on Cancer Behavior in Cancer Patients Undergoing Chemotherapy: A Prospective Follow-Up Study
NCT06744803CI-TRIAL-00083995not yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will be conducted to determine the effect of a gamified neuropathy management application on cancer behavior in cancer patients undergoing chemotherapy.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Chemotherapy Induced Pain Neuropathy | — | UNRESOLVED | — |
| Gamification | — | UNRESOLVED | — |
| Nursing | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gamified Neuropathy Management Application on Cancer Behavior | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- intervention group
- description
- Gamified Neuropathy Management Application
- interventionNames
- Behavioral: Gamified Neuropathy Management Application on Cancer Behavior
- type
- NO_INTERVENTION
- label
- control group
- description
- no intervention
Primary outcomes (3)
- measure
- The effect of gamified neuropathy management application on chemotherapy-associated peripheral neuropathic pain.
- timeFrame
- 6 months
- description
- DN4 Questionnaire: The DN4 pain questionnaire, developed by the French neuropathic pain group, is a questionnaire that includes symptoms and findings associated with neuropathic pain. The individual being evaluated answers the questions with yes or no. The total scale score is calculated by giving 1 point for each yes answer and 0 point for each no answer. In the scale, the cutoff value for neuropathic pain is determined as 4/10 and above. Turkish validity and reliability was determined by Unal-Çevik et al. It was made by and the Cronbach alpha coefficient was 0.97; The specificity and sensitivity in diagnosing neuropathic pain were found to be 96.6% and 95%, respectively.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Undergoing chemotherapy treatment and have completed their first cycle. * Literate (able to read and write). * Able to use a smartphone. * Aged between 18 and 65 years. * Willing to participate in the study voluntarily. Exclusion Criteria: * Participants who do not use the application during the study period * Participants who fail to complete the data collection forms
References
Publications (0)
Data not yet available
No reference posted for this study.